Cargando…

Antimicrobial peptides and the gut microbiome in inflammatory bowel disease

Antimicrobial peptides (AMP) are highly diverse and dynamic molecules that are expressed by specific intestinal epithelial cells, Paneth cells, as well as immune cells in the gastrointestinal (GI) tract. They play critical roles in maintaining tolerance to gut microbiota and protecting against enter...

Descripción completa

Detalles Bibliográficos
Autores principales: Gubatan, John, Holman, Derek R, Puntasecca, Christopher J, Polevoi, Danielle, Rubin, Samuel JS, Rogalla, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613745/
https://www.ncbi.nlm.nih.gov/pubmed/34887639
http://dx.doi.org/10.3748/wjg.v27.i43.7402
_version_ 1784603700921106432
author Gubatan, John
Holman, Derek R
Puntasecca, Christopher J
Polevoi, Danielle
Rubin, Samuel JS
Rogalla, Stephan
author_facet Gubatan, John
Holman, Derek R
Puntasecca, Christopher J
Polevoi, Danielle
Rubin, Samuel JS
Rogalla, Stephan
author_sort Gubatan, John
collection PubMed
description Antimicrobial peptides (AMP) are highly diverse and dynamic molecules that are expressed by specific intestinal epithelial cells, Paneth cells, as well as immune cells in the gastrointestinal (GI) tract. They play critical roles in maintaining tolerance to gut microbiota and protecting against enteric infections. Given that disruptions in tolerance to commensal microbiota and loss of barrier function play major roles in the pathogenesis of inflammatory bowel disease (IBD) and converge on the function of AMP, the significance of AMP as potential biomarkers and novel therapeutic targets in IBD have been increasingly recognized in recent years. In this frontier article, we discuss the function and mechanisms of AMP in the GI tract, examine the interaction of AMP with the gut microbiome, explore the role of AMP in the pathogenesis of IBD, and review translational applications of AMP in patients with IBD.
format Online
Article
Text
id pubmed-8613745
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-86137452021-12-08 Antimicrobial peptides and the gut microbiome in inflammatory bowel disease Gubatan, John Holman, Derek R Puntasecca, Christopher J Polevoi, Danielle Rubin, Samuel JS Rogalla, Stephan World J Gastroenterol Frontier Antimicrobial peptides (AMP) are highly diverse and dynamic molecules that are expressed by specific intestinal epithelial cells, Paneth cells, as well as immune cells in the gastrointestinal (GI) tract. They play critical roles in maintaining tolerance to gut microbiota and protecting against enteric infections. Given that disruptions in tolerance to commensal microbiota and loss of barrier function play major roles in the pathogenesis of inflammatory bowel disease (IBD) and converge on the function of AMP, the significance of AMP as potential biomarkers and novel therapeutic targets in IBD have been increasingly recognized in recent years. In this frontier article, we discuss the function and mechanisms of AMP in the GI tract, examine the interaction of AMP with the gut microbiome, explore the role of AMP in the pathogenesis of IBD, and review translational applications of AMP in patients with IBD. Baishideng Publishing Group Inc 2021-11-21 2021-11-21 /pmc/articles/PMC8613745/ /pubmed/34887639 http://dx.doi.org/10.3748/wjg.v27.i43.7402 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Frontier
Gubatan, John
Holman, Derek R
Puntasecca, Christopher J
Polevoi, Danielle
Rubin, Samuel JS
Rogalla, Stephan
Antimicrobial peptides and the gut microbiome in inflammatory bowel disease
title Antimicrobial peptides and the gut microbiome in inflammatory bowel disease
title_full Antimicrobial peptides and the gut microbiome in inflammatory bowel disease
title_fullStr Antimicrobial peptides and the gut microbiome in inflammatory bowel disease
title_full_unstemmed Antimicrobial peptides and the gut microbiome in inflammatory bowel disease
title_short Antimicrobial peptides and the gut microbiome in inflammatory bowel disease
title_sort antimicrobial peptides and the gut microbiome in inflammatory bowel disease
topic Frontier
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613745/
https://www.ncbi.nlm.nih.gov/pubmed/34887639
http://dx.doi.org/10.3748/wjg.v27.i43.7402
work_keys_str_mv AT gubatanjohn antimicrobialpeptidesandthegutmicrobiomeininflammatoryboweldisease
AT holmanderekr antimicrobialpeptidesandthegutmicrobiomeininflammatoryboweldisease
AT puntaseccachristopherj antimicrobialpeptidesandthegutmicrobiomeininflammatoryboweldisease
AT polevoidanielle antimicrobialpeptidesandthegutmicrobiomeininflammatoryboweldisease
AT rubinsamueljs antimicrobialpeptidesandthegutmicrobiomeininflammatoryboweldisease
AT rogallastephan antimicrobialpeptidesandthegutmicrobiomeininflammatoryboweldisease